Factors influencing credentialing of interventionists in the CREST-2 trial Article

Full Text via DOI: 10.1016/j.jvs.2019.05.035 PMID: 31353274 Web of Science: 000514846800034

Cited authors

  • Lal, Brajesh K.; Meschia, James F.; Roubin, Gary S.; Jankowitz, Brian; Heck, Donald; Jovin, Tudor; White, Christopher J.; Rosenfield, Kenneth; Katzen, Barry; Dabus, Guilherme; Gray, William; Matsumura, Jon; Hopkins, L. Nelson; Luke, Sothear; Sharma, Jashank; Voeks, Jenifer H.; Howard, George; Brott, Thomas G.

Abstract

  • Background: The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is a pair of randomized trials assessing the relative efficacy of carotid revascularization in the setting of intensive medical management (IMM) in patients with asymptomatic high-grade atherosclerotic stenosis. One of the trials assesses IMM with or without carotid artery stenting (CAS). Given the low risk of stroke in nonrevascularized patients receiving IMM, it is essential that there be low periprocedural risk of stroke for CAS if it is to show incremental benefit. Thus, credentialing of interventionists to ensure excellence is vital. This analysis describes the protocol-driven approach to credentialing of CAS interventionists for CREST-2 and its outcomes.; Methods: To be eligible to perform stenting in CREST-2, interventionists needed to be credentialed on the basis of a detailed Interventional Management Committee (IMC) review of data from their last 25 consecutive cases during the past 24 months along with self-reported lifetime experience case numbers. When necessary, additional prospective cases performed in a companion registry were requested after webinar training. Here we review the IMC experience from the first formal meeting on March 21, 2014 through October 14, 2017.; Results: The IMC had 102 meetings, and 8311 cases submitted by 334 interventionists were evaluated. Most were either cardiologists or vascular surgeons, although no single specialty made up the majority of applicants. The median total experience was 130 cases (interquartile range [IQR], 75-266; range, 25-2500). Only 9% (30/334) of interventionists were approved at initial review; approval increased to 46% (153/334) after submission of new cases with added training and re-review. The median self-reported lifetime case experience for those approved was 211.5 (IQR, 100-350), and the median number of cases submitted for review was 30 (IQR, 27-35). The number of CAS procedures performed per month (case rate) was the only factor associated with approval during the initial cycle of review (P <.00001).; Conclusions: Identification of interventionists who were deemed sufficiently skilled for CREST-2 has required substantial oversight and a controlled system to judge current skill level that controls for specialty-based practice variability, procedural experience, and periprocedural outcomes. High-volume interventionists, particularly those with more recent experience, were more likely to be approved to participate in CREST-2. Primary approval was not affected by operator specialty.

Authors

Publication date

  • 2020

Published in

International Standard Serial Number (ISSN)

  • 0741-5214

Start page

  • 854

End page

  • 861

Volume

  • 71

Issue

  • 3